Skip to content

REmote Symptom COllection to improVE postopeRative Care

REmote Symptom COllection to improVE postopeRative Care

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06190730
Acronym
RECOVER
Enrollment
281
Registered
2024-01-05
Start date
2024-07-23
Completion date
2027-12-31
Last updated
2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer, Gastrointestinal Surgery, Gastrointestinal Tumor, Gastrointestinal Tumor Surgery

Keywords

speech system, large language model, ai

Brief summary

There are vulnerabilities in post-discharge care transition for patients after undergoing resection of malignant gastrointestinal tumors. This study aims to investigate the possibility of utilizing Voice-Assisted Remote Symptom Monitoring System (VARSMS) to alleviate some of these challenges.

Detailed description

Randomized controlled trial comparing post-op patients randomized to using the VARSMS vs control.

Interventions

OTHERVoice-Assisted Remote Symptom Monitoring System (VARSMS)

Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.

Sponsors

Medstar Health Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The Voice-Assisted Remote Symptom Monitoring System (VARSMS) will be installed on Amazon Echo Dot

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. At least 18 years old. Ages of subjects \>89 will simply be reported as \>90. 2. Scheduled for a GI surgery for management of a tumor in a participating hospital. 3. Fluent in oral and written English. 4. Has consistent and continued full access to an operational Wi-Fi for the duration of the study.

Exclusion criteria

1. Unable to provide informed consent. 2. Not willing to commit to regular participation in the study to include daily use (40 days) of the study application. 3. Life expectancy of less than 60 days. 4. In the opinion of the investigator, participation in this study is contraindicated.

Design outcomes

Primary

MeasureTime frameDescription
Custom questionnaire based on NCI PRO CTCAE (National Cancer Institute- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)40 daysDaily symptom-based self-reported assessment on dyspnea, fever, melena, pain, wound healing, activities of daily living, sensorium, gastrointestinal motility, dysphagia, pitting edema, mood, and an option to mention symptoms not asked of. This is monitored by the research team, and any concerning finding, at the discretion of the site's physician, will be relayed to the subject's treating physician. Treating physician has final decision on whether to address referral by adjustment of management.

Secondary

MeasureTime frameDescription
SASSI (Subjective Assessment of Speech System Interfaces)40 daysAfter interacting with the speech system for 40 days from the day after discharge, this questionnaire assesses the patient on their experience, having them rate the system based on system response accuracy, likeability, cognitive demand, annoyance, habitability, and speed.

Countries

United States

Contacts

Primary ContactNawar Shara, PhD
nawar.shara@medstar.net301-502-0339
Backup ContactCrisanto Macaraeg, MD
crisanto.l.macaraeg@medstar.net410-261-8218

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026